ResearchPod Summary
The ovarian reserve—the pool of primordial follicles (PMFs) formed before birth—is highly sensitive to cancer treatments, including chemotherapy and radiotherapy. This sensitivity often leads to premature ovarian insufficiency (POI), where the exhaustion of the follicular pool results in early menopause and infertility. The drugs commonly linked to these adverse effects include alkylating agents like cyclophosphamide (CPM), platinum complexes like cisplatin (CIS), and anthracyclines like doxorubicin (DOX).
Damage occurs via both direct and indirect pathways. Chemotherapy agents directly induce DNA damage and apoptosis in oocytes and surrounding granulosa cells. Additionally, chemotherapy can trigger the "burnout" of the follicle reserve by inducing the accelerated activation of dormant primordial follicles. This is often mediated by dysregulation of the PI3K/PTEN/Akt/FOXO3a pathway, which governs follicle quiescence. Beyond follicle-specific effects, chemotherapy damages the ovarian vasculature and stromal compartment, which may further impair follicle survival and development.
Research has increasingly focused on identifying pharmacological "adjuvants"—agents administered alongside chemotherapy to protect the ovary. These include:
For cancer patients, fertility preservation is a critical component of quality of life and long-term health. While cryopreservation of oocytes, embryos, and ovarian tissue are established techniques, these methods are not suitable or accessible for all patients. Pharmacological protection of the ovary during active treatment would represent a significant breakthrough, potentially allowing patients to retain natural fertility and endocrine function without the invasive procedures associated with tissue storage. However, the field is currently in an early stage; many promising agents have only been validated in rodents, and their safety—specifically regarding potential interference with cancer treatment efficacy or long-term risks to the offspring—remains a major question for future clinical translation.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.